AGN addendum: Compared to most drug/biotech companies, AGN has a track record of being conservative in its EPS guidance. AGN almost always beats its EPS guidance handily, and hence the true forward P/E is somewhat less than the 20x figure mentioned in #msg-59583715.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”